MacroGenics (MGNX) Reports Q4 Loss, Lags Revenue Estimates

Financial Performance - MacroGenics reported a quarterly loss of $0.25 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.23, but an improvement from a loss of $0.75 per share a year ago [1] - The company posted revenues of $19.35 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 57.24%, compared to revenues of $10.72 million a year ago [2] - Over the last four quarters, MacroGenics has surpassed consensus EPS estimates only once [2] Stock Performance - MacroGenics shares have declined approximately 32.9% since the beginning of the year, while the S&P 500 has decreased by 3.5% [3] - The current Zacks Rank for MacroGenics is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.70 on revenues of $21.5 million, and for the current fiscal year, it is -$2.46 on revenues of $91.14 million [7] - The estimate revisions trend for MacroGenics is mixed, and future stock movements will depend on management's commentary during the earnings call [3][4] Industry Context - The Medical - Products industry, to which MacroGenics belongs, is currently ranked in the bottom 49% of over 250 Zacks industries, which may impact the stock's performance [8] - Another company in the same industry, Abbott, is expected to report quarterly earnings of $1.07 per share, reflecting a year-over-year change of +9.2% [9]